Product Usage: This product is intended for research purposes only.
All product information available on this website is for educational purposes only. Any form of bodily introduction into humans or animals is strictly prohibited by law. This product should only be handled by licensed and qualified professionals. It is not a drug, food, or cosmetic, and must not be misbranded, misused, or mislabeled as such.
IGF-1 LR3 1mg
During our packaging transition, you may receive products with either our previous or updated label. Rest assured, the formulation, purity and quality remain exactly same as standards.
IGF-1 LR3 (Long Arg3-IGF-1) is a synthetic 83-amino-acid analogue of insulin-like growth factor 1, engineered with an N-terminal 13-amino-acid extension and an Arg3 substitution that together confer markedly reduced affinity for IGF-binding proteins (IGFBPs) and extended plasma half-life. These modifications preserve IGF-1 receptor (IGF-1R) agonist activity while reducing IGFBP sequestration, enabling sustained receptor engagement in preclinical research models.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
| Chemical Formula | C400H625N111O115S9 |
|---|---|
| Synonyms | Long R3-IGF-1, M9L22Y19H9, 143045-27-6, Long-(arg3)insulin-like growth factor-i |
| Molar Mass | 9,117.60 g/mol |
| CAS Number | 143045-27-6 |
| PubChem CID | 381123731 |
| Total Compound Content | 1 mg per vial |
| Shelf Life | 36 months |
Every batch is independently lab tested for identity, purity and potency. View our lab testing program →
Why does IGF-1 LR3 have a longer half-life than native IGF-1?
Native IGF-1 is rapidly sequestered in circulation by IGF-binding proteins (IGFBPs 1–6), which extend its half-life but also restrict bioavailability. The Arg3 substitution and N-terminal 13-residue extension in IGF-1 LR3 reduce IGFBP affinity by approximately 1,000-fold, preventing this sequestration. Without IGFBP binding, IGF-1 LR3 remains in free, receptor-accessible form for 56–72 hours — substantially longer than native IGF-1's 10–20-minute half-life when not IGFBP-bound.
Which intracellular signalling pathways does IGF-1 LR3 activate via IGF-1R?
IGF-1R is a receptor tyrosine kinase. Ligand binding drives receptor autophosphorylation, IRS-1/IRS-2 adapter recruitment, and activation of two primary downstream cascades: PI3K/Akt/mTOR (governing protein synthesis, glucose uptake, and cell survival) and MAPK/ERK (regulating cell proliferation and differentiation). Both pathways are fully engaged by IGF-1 LR3 at the IGF-1R, identical to native IGF-1.
What types of experimental programs are most suited to the IGF-1 LR3 10-vial KIT format?
The IGF-1 LR3 KIT format is particularly useful for longitudinal investigations, multi-arm experimental designs, concentration-response studies, receptor-signaling experiments, and pathway-characterization programs that require repeated compound preparation over extended periods. The availability of multiple matched-batch vials supports consistent experimental conditions across separate study phases, treatment groups, and sampling timepoints. This makes the KIT format well-suited to research involving IGF-1 receptor signaling, PI3K/Akt/mTOR pathway analysis, MAPK/ERK pathway investigation, and comparative insulin-like growth factor pharmacology.
-
SALE
-
-
SALE
-
-
-
